| Product Name | Anti-Rh D Blood Group/CD240D antigen Monoclonal Antibody |
|---|---|
| Description | Human heterohybridoma to human Rh D (ISBT4001)/CD240CD blood group-related antigen Affinity purified. The Rh D antigen (Rh1 or Rho ) is clinically the most important of the Rh blood group system. It is expressed on the extracellular loops of a transmembrane polypeptide of around Mr 30000. Estimated numbers of Rh D sites recognised by BRAD-3 on Rh D positive cells are between 10000 to 14000 on CDe/cde (R1r) cells and 27000 to 33000 on cDE/cDE (R2R2) cells. |
| Synonyms | Rh D blood group antigen, CD240 |
| Clonality | Monoclonal |
| Clone | BRAD-3 |
| Immunogen | Rh D antigen produced by an EBV transformed B cell line derived from the peripheral blood of immunized RhD negative donor. |
| Isotype | Human IgG3 kappa light chain |
| Reactivity | Human |
| Applications | FC, ICC, IP, WB |
| Form | Affinity purified, in 0.1 M glycine buffer, 1 M Tris buffer, pH 7.4, sterile filtered |
| Storage | 2-8C for immediate use, or at -2°C (aliquot) |
| References | Cartron, J-P, (1994) Blood Reviews 8, 199 Jones et al., (1996), Vox Sanguinis 71, 176-183 Kumpel et al., (1989) Br. J. Haematol. 71, 125 Jones J et al. (1995) Transfusion Medicine 5, 171-184 Lloyd-Evans et al., (1995), Transfusion Medicine 5, 171 Lloyd-Evans et al., (1996). Transfusion 36, 432-437 Lloyd-Evans P. et al, (1999) Transfusion Medicine 9 155-160 Kumpel B. (2001) Transfusion 41, 1059-1063 Chapman JF (1999) Working party of the BCSH Blood Transfusion and General Haematology Task Forces. Transfusion Medicine 9, 87-92 Austin E. et al. (2009) Guidelines for the estimation of fetomaternal haemorrhage. Working party of the BCSH Transfusion Taskforce. BCSH FMH Guidelines 2009 p1-23 Lloyd-Evans P. et al, (1999) Transfusion Medicine 9 suppl 1:33. 9. |
| Supplier | ARP |
All Research Products are sold for laboratory RESEARCH USE ONLY and ARE NOT TO BE USED FOR HUMAN OR ANIMAL THERAPEUTIC OR DIAGNOSTIC APPLICATIONS. The information presented is believed to be accurate; however, said information and products are offered without warranty or guarantee since the ultimate conditions of use and the variability of the materials treated are beyond our control. Nothing disclosed herein is to be construed as a recommendation to use our products in violation of any patents. ARP American Research Products, Inc. does not submit its products for regulatory review by any government body or other organization, and we do not validate them for clinical, therapeutic or diagnostic use, or for safety and effectiveness. You are solely responsible for making sure that the way you use the products complies with applicable laws, regulations and governmental policies and for obtaining all necessary approvals, intellectual property rights, licenses and permissions that you may need related to your use. Under no circumstances shall ARP American Research Products, Inc. be liable for damages, whether consequential, compensatory, incidental or special, strict liability or negligence, breach of warranty or any other theory arising out of the use of the products available from ARP American Research Products, Inc. Nothing contained herein warrants that the use of the products will not infringe on the claims of any patents covering the product itself or the use thereof in combination with other products or in the operation of any process. ARP American Research Products, Inc. disclaims any and all representations or warranties of any kind whatsoever, express or implied, including without limitation any implied warranties of merchantability or fitness for a particular purpose, of non-infringement, or regarding results obtained through the use of any product, whether arising from a statute or otherwise in law or from a course of performance, dealing or usage of trade.
